子癇前症診断のグローバル市場(2022ー2031年):血液検査、尿検査、その他

• 英文タイトル:Preeclampsia Diagnostics Market (Test Type: Blood Test, Urine Test, and Others; Product & Services: Instruments, Reagents & Consumables, and Services) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Preeclampsia Diagnostics Market (Test Type: Blood Test, Urine Test, and Others; Product & Services: Instruments, Reagents & Consumables, and Services) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031「子癇前症診断のグローバル市場(2022ー2031年):血液検査、尿検査、その他」(市場規模、市場予測)調査レポートです。• レポートコード:MRC2301F0087
• 出版社/出版日:Transparency Market Research / 2022年11月16日
• レポート形態:英文、PDF、176ページ
• 納品方法:Eメール
• 産業分類:医薬品
• 販売価格(消費税別)
  Single User¥869,250 (USD5,795)▷ お問い合わせ
  Multi User¥1,319,250 (USD8,795)▷ お問い合わせ
  Corporate License¥1,769,250 (USD11,795)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
Transparency Market Research社では、世界の子癇前症診断市場を調査対象とし、序論、仮定・調査手法、市場概要、主要インサイト、検査タイプ別分析(血液検査、尿検査、その他)、製品&サービス別分析(機器、試薬&消費品、サービス)、エンドユーザー別分析(病院、診断センター、その他)、地域別分析(北米、ヨーロッパ、アジア太平洋、中南米、中東/アフリカ)、競争状況、企業情報などについて総合的に調査・分析をしました。なお、当書には、Abbott Laboratories、Danaher Corporation (Beckman Coulter, Inc.)、Siemens Healthineers AG、Cardinal Health、F. Hoffmann-La Roche Ltd.、Bio-Rad Laboratories, Inc.、ARKRAY, Inc.、Sera Prognostics、Metabolomic Diagnostics Ltd.、Diabetomics, Inc.などの主要企業情報が含まれています。
・序論
・仮定・調査手法
・市場概要
・主要インサイト

・世界の子癇前症診断市場規模:検査タイプ別
- 血液検査の市場規模
- 尿検査の市場規模
- その他検査タイプの市場規模

・世界の子癇前症診断市場規模:製品&サービス別
- 機器の市場規模
- 試薬&消費品の市場規模
- サービスの市場規模

・世界の子癇前症診断市場規模:エンドユーザー別
- 病院における市場規模
- 診断センターにおける市場規模
- その他エンドユーザーにおける市場規模

・世界の子癇前症診断市場規模:地域別
- 北米の子癇前症診断市場規模
- ヨーロッパの子癇前症診断市場規模
- アジア太平洋の子癇前症診断市場規模
- 中南米の子癇前症診断市場規模
- 中東/アフリカの子癇前症診断市場規模

・競争状況
・企業情報

Preeclampsia Diagnostics Market – Scope of Report
TMR’s report on the global preeclampsia diagnostics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global preeclampsia diagnostics market for the period 2017–2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global preeclampsia diagnostics market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the preeclampsia diagnostics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global preeclampsia diagnostics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global preeclampsia diagnostics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global preeclampsia diagnostics market.

The report delves into the competitive landscape of the global preeclampsia diagnostics market. Key players operating in the global preeclampsia diagnostics market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global preeclampsia diagnostics market profiled in this report.

RESEARCH METHODOLOGY

The research methodology will be a combination of exhaustive primary and secondary research to analyze the market preeclampsia diagnostics.

Secondary Research

Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.

Secondary research sources that we typically refer, but are not limited to:

Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market

Specific Secondary Sources:

Industry Sources:
WorldWideScience.org
Elsevier, Inc.
National Institutes of Health (NIH)
PubMed
NCBI
Department of Health Care Service
Trade Data Sources
Trade Map
UN Comtrade
Trade Atlas
Company Information
OneSource Business Browser
Hoover’s
Factiva
Bloomberg
Mergers & Acquisitions
Thomson Mergers & Acquisitions
MergerStat
Profound

Primary Research

During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.

We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:

Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies

Participants who typically take part in such a process include, but are not limited to:

Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals

List of primary participants, but not limited to:

Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.

Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.

Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:

Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities

Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.

レポート目次

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Preeclampsia Diagnostics Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Preeclampsia Diagnostics Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Technological Advancements
5.2. Disease Prevalence & Incidence Rate globally with key countries
5.3. Regulatory Scenario by Region/globally
5.4. Key Industry Events (Mergers, Acquisitions, Partnerships, Collaborations, etc.)
5.5. COVID-19 Pandemic Impact on Industry
6. Global Preeclampsia Diagnostics Market Analysis and Forecast, by Test Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Test Type, 2017–2031
6.3.1. Blood Test
6.3.2. Urine Test
6.3.3. Others
6.4. Market Attractiveness By Test Type
7. Global Preeclampsia Diagnostics Market Analysis and Forecast, by Product & Services
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Product & Services, 2017–2031
7.3.1. Instruments
7.3.2. Reagents & Consumables
7.3.3. Services
7.4. Market Attractiveness By Product & Services
8. Global Preeclampsia Diagnostics Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by End-user, 2017–2031
8.3.1. Hospitals
8.3.2. Diagnostic Centers
8.3.3. Others
8.4. Market Attractiveness By End-user
9. Global Preeclampsia Diagnostics Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness By Country/Region
10. North America Preeclampsia Diagnostics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Test Type, 2017–2031
10.2.1. Blood Test
10.2.2. Urine Test
10.2.3. Others
10.3. Market Value Forecast, by Product & Services, 2017–2031
10.3.1. Instruments
10.3.2. Reagents & Consumables
10.3.3. Services
10.4. Market Value Forecast, by End-user, 2017–2031
10.4.1. Hospitals
10.4.2. Diagnostic Centers
10.4.3. Others
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Test Type
10.6.2. By Product & Services
10.6.3. By End-user
10.6.4. By Country
11. Europe Preeclampsia Diagnostics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Test Type, 2017–2031
11.2.1. Blood Test
11.2.2. Urine Test
11.2.3. Others
11.3. Market Value Forecast, by Product & Services, 2017–2031
11.3.1. Instruments
11.3.2. Reagents & Consumables
11.3.3. Services
11.4. Market Value Forecast, by End-user, 2017–2031
11.4.1. Hospitals
11.4.2. Diagnostic Centers
11.4.3. Others
11.5. Market Value Forecast, by Country/Sub-Region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Test Type
11.6.2. By Product & Services
11.6.3. By End-user
11.6.4. By Country/Sub-Region
12. Asia Pacific Preeclampsia Diagnostics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Test Type, 2017–2031
12.2.1. Blood Test
12.2.2. Urine Test
12.2.3. Others
12.3. Market Value Forecast, by Product & Services, 2017–2031
12.3.1. Instruments
12.3.2. Reagents & Consumables
12.3.3. Services
12.4. Market Value Forecast, by End-user, 2017–2031
12.4.1. Hospitals
12.4.2. Diagnostic Centers
12.4.3. Others
12.5. Market Value Forecast, by Country/Sub-Region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Test Type
12.6.2. By Product & Services
12.6.3. By End-user
12.6.4. By Country/Sub-Region
13. Latin America Preeclampsia Diagnostics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Test Type, 2017–2031
13.2.1. Blood Test
13.2.2. Urine Test
13.2.3. Others
13.3. Market Value Forecast, by Product & Services, 2017–2031
13.3.1. Instruments
13.3.2. Reagents & Consumables
13.3.3. Services
13.4. Market Value Forecast, by End-user, 2017–2031
13.4.1. Hospitals
13.4.2. Diagnostic Centers
13.4.3. Others
13.5. Market Value Forecast, by Country/Sub-Region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Test Type
13.6.2. By Product & Services
13.6.3. By End-user
13.6.4. By Country/Sub-Region
14. Middle East & Africa Preeclampsia Diagnostics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Test Type, 2017–2031
14.2.1. Blood Test
14.2.2. Urine Test
14.2.3. Others
14.3. Market Value Forecast, by Product & Services, 2017–2031
14.3.1. Instruments
14.3.2. Reagents & Consumables
14.3.3. Services
14.4. Market Value Forecast, by End-user, 2017–2031
14.4.1. Hospitals
14.4.2. Diagnostic Centers
14.4.3. Others
14.5. Market Value Forecast, by Country/Sub-Region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Test Type
14.6.2. By Product & Services
14.6.3. By End-user
14.6.4. By Country/Sub-Region
15. Competition Landscape
15.1. Market Player – Competition Matrix (By Tier and Size of companies)
15.2. Company Profiles
15.2.1. Abbott Laboratories
15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.1.2. Product Portfolio
15.2.1.3. Financial Overview
15.2.1.4. SWOT Analysis
15.2.1.5. Strategic Overview
15.2.2. Danaher Corporation (Beckman Coulter, Inc.)
15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.2.2. Product Portfolio
15.2.2.3. Financial Overview
15.2.2.4. SWOT Analysis
15.2.2.5. Strategic Overview
15.2.3. Siemens Healthineers AG
15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.3.2. Product Portfolio
15.2.3.3. Financial Overview
15.2.3.4. SWOT Analysis
15.2.3.5. Strategic Overview
15.2.4. Cardinal Health
15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.4.2. Product Portfolio
15.2.4.3. Financial Overview
15.2.4.4. SWOT Analysis
15.2.4.5. Strategic Overview
15.2.5. F. Hoffmann-La Roche Ltd.
15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.5.2. Product Portfolio
15.2.5.3. Financial Overview
15.2.5.4. SWOT Analysis
15.2.5.5. Strategic Overview
15.2.6. Bio-Rad Laboratories, Inc.
15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.6.2. Product Portfolio
15.2.6.3. Financial Overview
15.2.6.4. SWOT Analysis
15.2.6.5. Strategic Overview
15.2.7. ARKRAY, Inc.
15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.7.2. Product Portfolio
15.2.7.3. Financial Overview
15.2.7.4. SWOT Analysis
15.2.7.5. Strategic Overview
15.2.8. Sera Prognostics
15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.8.2. Product Portfolio
15.2.8.3. Financial Overview
15.2.8.4. SWOT Analysis
15.2.8.5. Strategic Overview
15.2.9. Metabolomic Diagnostics Ltd.
15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.9.2. Product Portfolio
15.2.9.3. Financial Overview
15.2.9.4. SWOT Analysis
15.2.9.5. Strategic Overview
15.2.10. Diabetomics, Inc.
15.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.10.2. Product Portfolio
15.2.10.3. Financial Overview
15.2.10.4. SWOT Analysis
15.2.10.5. Strategic Overview
15.2.11. ACON Laboratories, Inc.
15.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.11.2. Product Portfolio
15.2.11.3. Financial Overview
15.2.11.4. SWOT Analysis
15.2.11.5. Strategic Overview
15.2.12. DIRUI Industrial Co., Ltd.
15.2.12.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.12.2. Product Portfolio
15.2.12.3. Financial Overview
15.2.12.4. SWOT Analysis
15.2.12.5. Strategic Overview

List of Tables

Table 01: Global Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017‒2031

Table 02: Global Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by Product & Services, 2017–2031

Table 03: Global Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 04: Global Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 05: North America Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 06: North America Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017‒2031

Table 07: North America Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by Product & Services, 2017–2031

Table 08: North America Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 09: Europe Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 10: Europe Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017‒2031

Table 11: Europe Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by Product & Services, 2017–2031

Table 12: Europe Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 13: Asia Pacific Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 14: Asia Pacific Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017‒2031

Table 15: Asia Pacific Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by Product & Services, 2017–2031

Table 16: Asia Pacific Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 17: Latin America Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 18: Latin America Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017‒2031

Table 19: Latin America Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by Product & Services, 2017–2031

Table 20: Latin America Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 21: Middle East & Africa Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017‒2031

Table 22: Middle East & Africa Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017‒2031

Table 23: Middle East & Africa Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by Product & Services, 2017–2031

Table 24: Middle East & Africa Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031


• 英文レポート名:Preeclampsia Diagnostics Market (Test Type: Blood Test, Urine Test, and Others; Product & Services: Instruments, Reagents & Consumables, and Services) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
• 日本語訳:子癇前症診断のグローバル市場(2022ー2031年):血液検査、尿検査、その他
• レポートコード:MRC2301F0087お問い合わせ(見積依頼・ご注文・質問)